Document:

EX-10.9

 Exhibit 10.9 

AMENDMENT NO. 1 
 TO

 LOAN AND SECURITY AGREEMENT EXTENSION 

THIS AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is made and entered into as of September 30,
2021, by and among Heart Test Laboratories, Inc., a Texas corporation, (the “Company”), Front Range Ventures LLC, a Wyoming limited liability company, or its assigns (“FRV”), and John Q. Adams, a Texas resident, or
his assigns, (“JQA”) (FRV and JQA each a “Lender” and together the “Lenders”) as defined in the Original Agreement (as defined below). 

WITNESSETH: 
 WHEREAS, the
Company, the Lenders (collectively, the “Parties”) have previously entered into a Loan and Security Escrow Agreement dated on or around April 24, 2020 (the “Original Agreement”); and 

WHEREAS, the Parties desire to extend the Maturity Date of the Original Agreement and the Original Agreement shall be repayable upon demand as
set forth in this Amendment. 
 NOW THEREFORE, in consideration of the issuance of warrants to acquire 500,000 shares of common stock of the
Company on terms set out in a separate warrant agreement and the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each party hereto, the Parties
hereby agree as follows: 
 Section 1. Capitalized Terms. Capitalized terms used in this Amendment shall have the meaning set
forth in the Original Agreement except as otherwise defined in this Amendment. 
 Section 2. Amendment. The Original Agreement
is hereby amended, as follows: 
 (a) Paragraph 3.1 of the Original Agreement is hereby amended to read, in its entirety, as follows: 

“The outstanding Principal Amount together with all Accrued Interest thereon shall be due and payable upon demand by the Lenders
(“Maturity Date”). All payments and other charges due and payable un the Transaction Agreements shall be made in the lawful currency of the United States of America” 

Section 3. Release or Claims Against Lenders. 

THE COMPANY, BY SIGNING THIS AMENDMENT, HEREBY ABSOLUTELY AND UNCONDITIONALLY RELEASES AND FOREVER DISCHARGES LENDERS AND ANY AND ALL
OF THEIR PARENT COMPANIES, SUBSIDIARY COMPANIES, AFFILIATED COMPANIES, INSURERS, INDEMNITORS, SUCCESSORS AND ASSIGNS TOGETHER 

 
WITH ALL OF THEIR RESPECTIVE PRESENT AND FORMER MANAGERS, DIRECTORS, OFFICERS, AGENTS AND EMPLOYEES FROM ANY AND ALL CLAIMS, DEMANDS OR CAUSES OF ACTION OF ANY KIND, NATURE OR DESCRIPTION,
WHETHER ARISING IN LAW OR EQUITY OR UPON CONTRACT OR TORT OR UNDER ANY STATE OR FEDERAL LAW OR OTHERWISE, WHICH THE COMPANY HAS HAD, NOW HAS, OR HAS MADE CLAIM TO HAVE AGAINST ANY SUCH PARTY FOR OR BY REASON OF ANY ACT, OMISSION, MATTER, CAUSE OR
THING WHATSOEVER ARISING FROM THE BEGINNING OF TIME TO AND INCLUDING THE DATE OF THIS AMENDMENT, WHETHER SUCH CLAIMS, DEMANDS AND CAUSES OF ACTION ARE MATURED OR UNMATURED OR KNOWN OR UNKNOWN. 

Section 4. Execution in Several Counterparts. This Amendment may be executed in several counterparts or by separate instruments
and by facsimile transmission and all of such counterparts and instruments shall constitute one agreement, binding on all of the Parties hereto. 

Section 5. Headings. The headings in this Amendment are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof. 
 Section 6. Governing Law. The laws of the State of Texas shall govern this Amendment without regard to
principles of conflict of laws. 
 Section 7. Original Agreement. Except as expressly amended by this Amendment, the Original
Agreement shall remain in full force and effect and all of the terms of the Original Agreement are hereby incorporated into this Amendment. 

[Remainder of this page deliberately left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the day and
year first above written. 
  

			
	COMPANY:
	
	HEART TEST LABORATORIES, INC.
		
	By:	 	 /s/ Mark Hilz

	Printed:	 	 Mark T. Hilz

	Title:	 	 CEO

	
	LENDER:
	
	FRONT RANGE VENTURES, LLC.
		
	By:	 	 /s/ Loren J. Richards

	Printed:	 	 Loren J. Richards

	Title:	 	 FWTB Trust Offier

	
	LENDER:
	
	JOHN Q. ADAMS
		
	By:	 	 /s/ John Q. Adams Sr.

	Printed:	 	  

	Title:EX-10.10

 Exhibit 10.10 

AMENDMENT NO. 2 
 TO

 LOAN AND SECURITY AGREEMENT 

THIS AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENT (this “No.2 Amendment”) is made and entered into as of November 3,
2021, by and among Heart Test Laboratories, Inc., a Texas corporation, (the “Company”), Front Range Ventures LLC, a Wyoming limited liability company, or its assigns (“FRV”), and John Q. Adams, a Texas resident, or
his assigns, (“JQA”) (FRV and JQA each a “Lender” and together the “Lenders”) as defined in the Original Agreement (as defined below). 

WITNESSETH: 
 WHEREAS, the
Company, the Lenders (collectively, the “Parties”) have previously entered into that certain Loan and Security Agreement dated on or around April 24, 2020 (the “Original Agreement”) and Amendment No. 1 to
the Loan and Security Agreement dated September 30, 2021 (“No.1 Amendment”) (together the “Loan Agreement”); and 

WHEREAS, the Company desires to further extend the Maturity Date as provided in the Loan Agreement to September 30, 2022; and 

WHEREAS, in consideration for Lender’s agreement to further extend the Maturity Date, the Company shall issue to each Lender a warrant as
specifically provided in those certain Warrant Agreements between the Company and each Lender and dated as of the date hereof. 
 NOW,
THEREFORE, in consideration of the foregoing, and the representations, warranties, covenants and conditions set forth herein, the Loan Agreement, and the other Transaction Agreements, the Company and the Lenders, intending to be legally bound,
hereby agree as follows: 
 Section 1. Capitalized Terms. Except as otherwise provided herein, capitalized terms used in this
No.2 Amendment shall have the meaning set forth in the Loan Agreement. 
 Section 2. Amendment. The Section 3.1 of the Loan
Agreement is hereby amended to read, in its entirety, as follows: 
 “3.1 Maturity Date. The outstanding Principal Amount,
together with all Accrued Interest thereon, shall be due and payable on September 30, 2022 (the “Maturity Date”). All payments and other charges due under the Transaction Agreements shall be made in lawful currency of the
United States of America.” 

 Section 3. Release of Claims Against Lenders. 

THE COMPANY, BY SIGNING THIS No.2 AMENDMENT, HEREBY ABSOLUTELY AND UNCONDITIONALLY RELEASES AND FOREVER DISCHARGES LENDERS AND ANY AND ALL OF
THEIR PARENT COMPANIES, SUBSIDIARY COMPANIES, AFFILIATED COMPANIES, INSURERS, INDEMNITORS, SUCCESSORS AND ASSIGNS TOGETHER WITH ALL OF THEIR RESPECTIVE PRESENT AND FORMER MANAGERS, DIRECTORS, OFFICERS, AGENTS AND EMPLOYEES FROM ANY AND ALL CLAIMS,
DEMANDS OR CAUSES OF ACTION OF ANY KIND, NATURE OR DESCRIPTION, WHETHER ARISING IN LAW OR EQUITY OR UPON CONTRACT OR TORT OR UNDER ANY STATE OR FEDERAL LAW OR OTHERWISE, WHICH THE COMPANY HAS HAD, NOW HAS, OR HAS MADE CLAIM TO HAVE AGAINST ANY SUCH
PARTY FOR OR BY REASON OF ANY ACT, OMISSION, MATTER, CAUSE OR THING WHATSOEVER ARISING FROM THE BEGINNING OF TIME TO AND INCLUDING THE DATE OF THIS AMENDMENT, WHETHER SUCH CLAIMS, DEMANDS AND CAUSES OF ACTION ARE MATURED OR UNMATURED OR KNOWN OR
UNKNOWN. 
 Section 4. Execution in Several Counterparts. This No.2 Amendment may be executed in several counterparts or by
separate instruments and by facsimile transmission and all of such counterparts and instruments shall constitute one agreement, binding on all of the Parties hereto. 

Section 5. Headings. The headings in this No.2 Amendment are for convenience of reference only and shall not limit or otherwise
affect the meaning hereof. 
 Section 6. Governing Law. The laws of the State of Texas shall govern this No.2 Amendment without
regard to principles of conflict of laws. 
 Section 7. Original Agreements. Except as expressly amended by this No.2 Amendment,
the Transaction Agreements shall remain in full force and effect and all of the terms of the Transaction Agreements are hereby incorporated into this No.2 Amendment. 

[Remainder of this page deliberately left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this No.2 Amendment as of the day
and year first above written. 
  

			
	COMPANY:
	
	HEART TEST LABORATORIES, INC.
		
	By:	 	 /s/ Andrew Simpson

	Printed:	 	 Andrew Simpson

	Title:	 	 Chairman

	
	LENDER:
	
	FRONT RANGE VENTURES, LLC.
		
	By:	 	 /s/ Loren J. Richards

	Printed:	 	 Loren J. Richards

	Title:	 	 First Western Trust Bank, Trust Offier

	
	LENDER:
	
	JOHN Q. ADAMS
		
	By:	 	 /s/ John Q. Adams Sr.

	Printed:	 	 John Q. Adams Sr.

	Title:EX-10.11

 Exhibit 10.11 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE
SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR BORROWER SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. 
 SECURED CONVERTIBLE PROMISSORY NOTE 

 

			
	$______________	  	Issuance Date: ________________

 FOR VALUE RECEIVED, the undersigned, Heart Test Laboratories, Inc. d/b/a HeartSciences, a Texas
corporation (“Borrower” or “Company”), hereby promises to pay to the order of __________________, or any future permitted holder of this promissory note (collectively, the “Holder”), at
_____________________________, or at such other place as the Holder may designate in writing to the Borrower, the principal sum of _______________Thousand and No/100 Dollars ($________________), and such other amount as may be outstanding hereunder,
together with all accrued but unpaid interest, in United States dollars, as provided in this Secured Convertible Promissory Note (the “Note”). 

THE PARTIES INTEND THIS INSTRUMENT TO BE EQUITY FOR TAX PURPOSES. 

This Note is one of a series (the “Series”) of secured convertible promissory notes (collectively, the “Series
Notes”) issued by the Company on the same terms. 
 1. Principal and Interest Payments. 

(a) The principal of this Note shall be due and payable on July 31, 2022 (the “Maturity Date”). 

(b) The parties intend this instrument to be equity for tax for purposes and it is expected that the Note shall be converted for equity in the
Borrower on or prior to the Maturity Date in which event no interest shall accrue and interest shall not be due or payable. 
 (c) In the
event the Note is not converted on or prior to the Maturity Date then interest shall accrue on the outstanding principal balance of this Note commencing on the date of this Note, at a simple interest a rate of twelve percent (12%) per annum.
Interest shall only be payable upon a repayment of the Note in cash by Borrower or upon an Event of Default. 
 (d) Borrower shall only make
interest and principal payments under this Note on a pro rata basis to the Series Notes based on the respective principal amounts of each Note. Each holder of a Note shall hold any amounts received in excess of its pro rata share in trust for the
benefit of the other holders of Series Notes. 

 (e) Borrower shall be entitled to repay the principal and all accrued but unpaid interest on
this Note in cash upon giving ten (10) days written notice to the Holder at any time upon or after any of the following events of the Borrower (“Borrower Repayment”): 

(i) 30 days following FDA clearance of the Borrower’s MyoVista product; 

(ii) the closing of further funding of $5 million or more which values entire share capital of the Borrower at
$50 million or more; 
 (iii) a public offering of Common Stock which values entire share capital of the Borrower at
$50 million or more; or 
 (iv) the sale or merger of a majority of the voting stock of the Borrower. 

2. Conversion. 
 (a)
Conversion of this Note shall be into shares of Common Stock of Borrower (the “Common Stock”) at a conversion price of Five Cents ($0.05 US Dollars) per share of Common Stock (“Conversion”) (as adjusted for any
splits, recapitalizations, combinations or other similar transactions affecting the Company’s Common Stock). 
 (b) Borrower may elect
for conversion of the principal balance of, and accrued but unpaid interest on, this Note at any time upon or after any of the following events of the Borrower (“Borrower Conversion”): 

(i) 30 days following FDA clearance of the Borrower’s MyoVista product; 

(ii) the closing of further funding of $5 million or more which values entire share capital of the Borrower at
$50 million or more; or 
 (iii) a public offering of Common Stock which values entire share capital of the Borrower at
$50 million or more. 
 (c) Holder shall be entitled to elect for voluntarily Conversion at any time upon written notice to the Company
(“Holder Conversion”). Such election shall be irrevocable and upon receipt of such written notice from the Holder Conversion shall be deemed to have automatically occurred. 

As soon as practicable following a Borrower Conversion, Borrower shall send written notice to Holder that such conversion has taken place and that the
principal balance of, and accrued but unpaid interest (if applicable under section 1(c)) on, this Note has been converted into shares of Common Stock. Upon Borrower Conversion or Holder Conversion the Borrower shall send written notice to the
Holder of the number of shares of Common Stock that Holder is entitled to receive upon such conversion (the “Conversion Shares”). Upon receipt by Borrower from Holder of the original copy of this Note, marked “Canceled”,
the Borrower will deliver to Holder a stock certificate evidencing the Conversion Shares. Notwithstanding anything in this Note to the 

  
 2 

 
contrary, effective as of the date that a Borrower Conversion or Holder Conversion, this Note shall be deemed to be canceled in its entirety and the only right of Holder thereafter is to receive
from Borrower a stock certificate evidencing the Conversion Shares (which stock certificate shall only be delivered to Holder upon Holder delivering to Borrower the original copy of this Note, marked “Canceled”). 

3. Non-Business Days. Whenever any payment to be made shall be due on a Saturday, Sunday or a
public holiday under the laws of the State of Texas, such payment may be due on the next succeeding business day and such next succeeding day shall be included in the calculation of the amount of accrued interest payable on such date. 

4. Events of Default. The occurrence of any of the following events shall be an “Event of Default” under this Note:

 (a) Borrower fails to make any payment on this Note as and when the same becomes due and payable in accordance with the terms hereof, if
the same has continued for five (5) days after written notice specifying such default has been delivered to the Borrower by Holder; 

(b) Borrower fails to perform any other covenant contained herein, if the same has continued for thirty (30) days after written notice
specifying such default has been delivered to the Borrower by Holder; 
 (c) Borrower shall (i) apply for or consent to the appointment
of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of all or a substantial part of its property or assets, (ii) make a general assignment for the benefit of its creditors, (iii) commence a
voluntary case under the Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or domestic), (iv) file a petition seeking to take advantage of any bankruptcy, insolvency, moratorium, reorganization or other similar law affecting
the enforcement of creditors’ rights generally, (v) acquiesce in writing to any petition filed against it in an involuntary case under the Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or domestic), or
(vi) take any action under the laws of any jurisdiction (foreign or domestic) analogous to any of the foregoing; or 
 (d) a proceeding
or case shall be commenced in respect of Borrower without its application or consent, in any court of competent jurisdiction, seeking (i) the liquidation, reorganization, moratorium, dissolution, winding up, or composition or readjustment of
its debts, (ii) the appointment of a trustee, receiver, custodian, liquidator or the like of it or of all or any substantial part of its assets or (iii) similar relief in respect of it under any law providing for the relief of debtors, and
such proceeding or case described in clause (i), (ii) or (iii) shall continue undismissed, or unstayed and in effect, for a period of thirty (30) consecutive days or any order for relief shall be entered in an involuntary case under the
Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or domestic) against Borrower or any of its subsidiaries or action under the laws of any jurisdiction (foreign or domestic) analogous to any of the foregoing shall be taken
with respect to Borrower or any of its subsidiaries and shall continue undismissed, or unstayed and in effect for a period of thirty (30) consecutive days. 

  
 3 

 5. Remedies Upon An Event of Default. If an Event of Default shall have
occurred and shall be continuing, Holder may at any time at its option, (a) declare the entire unpaid principal balance of this Note, together with all interest accrued hereon, due and payable, and thereupon, the same shall be accelerated and
so due and payable; provided, however, that upon the occurrence of an Event of Default described in (i) Sections 4(c) or (d) above, without presentment, demand, protest, or notice, all of which are hereby expressly
unconditionally and irrevocably waived by Borrower, the outstanding principal balance and accrued interest hereunder shall be automatically due and payable, and (ii) Sections 4(a) or (b) above, Holder may exercise or
otherwise enforce any one or more of Holder’s rights, powers, privileges, remedies and interests under this Note or applicable law. No course of delay on the part of Holder shall operate as a waiver thereof or otherwise prejudice the right of
Holder. No remedy conferred hereby shall be exclusive of any other remedy referred to herein or now or hereafter available at law, in equity, by statute or otherwise. 

6. Security Agreement. As collateral security for the full, prompt, complete and final payment and performance when due (whether at
stated maturity, by acceleration or otherwise) of all of the Borrower obligations under this Note and in order to induce the Holder to enter into the Note, the Borrower hereby assigns, conveys, mortgages, pledges, hypothecates and transfers to the
Series Note holders a security interest in all of the Borrower’s right, title and interest in, to and under all of the following property and assets, wherever located, whether now owned or hereafter acquired or arising, and all proceeds,
products, accessions, additions, substitutions, rents, profits and replacements thereof, including, without limitation, all Inventory, Equipment, Fixtures, Goods, Accounts, account receivables, contract rights, Commercial Tort Claims, chattel paper
(tangible and electronic), Deposit Accounts, Documents, General Intangibles, payment intangibles, Software, Instruments, Promissory Notes, Investment Property,
Letter-of-Credit Rights and letters-of-credit, and Supporting obligations, intellectual
property (including, and without limitation, patents, patent applications, copyrights, trademarks and trade secrets), license rights, distribution rights, and rights to sue for infringement of General Intangible or intellectual property rights (all
of which being collectively referred to herein as the “Collateral”). 
 (a) At any time and from time to time, upon
the written request of the Holder, the Company shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as the Holder may reasonably deem necessary or desirable to perfect and
continue perfected or better perfect the Holder’s liens in the Collateral. 
 (b) The Holder acknowledges that prior, senior security
interests in the Collateral described in this Section 6 have been granted as follows: 
 (i) to
Guangren “Gary” Chen pursuant to that certain Security Agreement and Pledge between Chen and Debtor dated as of March 14, 2014 (the “Chen Agreement”); and 

(ii) to Front Range Ventures, LLC and John Q. Adams pursuant to a Loan and Security Agreement dated as of April 24, 2020
(the “FRV/Adams Agreement”). 

  
 4 

 The Company represents and warrants that, except for the security interest granted hereunder and the prior
security interests granted under the Chen Agreement and FRV/Adams Agreement, the Company is the sole legal and equitable owner of each item of the Collateral in which it purports to grant a security interest hereunder. No other security agreement,
financing statement, equivalent security or lien instrument or continuation statement covering all or any part of the Collateral exists, except such as shall be filed in favor of the Series Note holders pursuant to the Series Notes or has been filed
pursuant to the Chen Agreement or FRV/Adams Agreement. 
 (c) Holder may exercise, in addition to and not in lieu of all other rights and
remedies granted to it hereunder and under the Notes, all rights and remedies of a secured party under the law, including the Uniform Commercial Code in effect in any and all jurisdictions where UCC-1s are
filed to perfect the Holders’ security interest (the “UCC”). The Holder shall not have any obligation or liability hereunder with respect to the Collateral. 

7. Miscellaneous. 

7.1 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Note will inure to the
benefit of, and be binding upon, the respective successors and assigns of the parties; provided, however, that the Company may not assign its obligations under this Note without the written consent of the holders of a
majority-in-interest of the aggregate principal amount of the Series Notes (the “Requisite Noteholders”). This Note is for the sole benefit of the
parties hereto and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or will confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever
under or by reason of this Note. 
 7.2 Choice of Law. This Note, and all matters arising out of or relating to this
Note, whether sounding in contract, tort, or statute will be governed by and construed in accordance with the internal laws of the State of Texas, without giving effect to the conflict of laws provisions thereof to the extent such principles or
rules would require or permit the application of the laws of any jurisdiction other than those of the State of Texas. 
 7.3
Counterparts. This Note may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. Counterparts may be delivered via facsimile, electronic mail
(including PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method, and any counterpart so delivered will be deemed to have been duly and validly delivered and be
valid and effective for all purposes. 
 7.4 Titles and Subtitles. The titles and subtitles used in this Note are
included for convenience only and are not to be considered in construing or interpreting this Note. 
 7.5 Notices.
All notices and other communications given or made pursuant hereto will be in writing and will be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent by email; (c) three (3) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d) one (1) day 

  
 5 

 
after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications will be sent to the respective parties at the
addresses shown on the signature pages hereto (or to such email address or other address as subsequently modified by written notice given in accordance with this Section 5.5). 

7.6 Expenses. Each party will pay all costs and expenses that it incurs with respect to the negotiation, execution,
delivery and performance of this Note. 
 7.7 Attorneys’ Fees. If any action at law or in equity is
necessary to enforce or interpret the terms of this Note, the prevailing party will be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

7.8 Entire Agreement; Amendments and Waivers. This Note constitutes the full and entire understanding and agreement
between the parties with regard to the subject hereof. The Borrower’s agreements with each of the holders of the Series Notes are separate agreements, and the sales of the Notes to each of the holders thereof are separate sales. Notwithstanding
the foregoing, any term of this Note and the other Series Notes may be amended and the observance of any term may be waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the
Borrower and the Requisite Noteholders. Any waiver or amendment effected in accordance with this Section 6.8 will be binding upon each holder of a Note in the Series and each future holder(s) of the Note and such Series
Notes. 
 7.9 Delivery of Financial Statements. If requested by the Holder, the Company will deliver to the Holder a
copy of the Company’s annual financial statements as such time as such financial statements are available to the Company. 

7.10 Severability. If one or more provisions of this Note are held to be unenforceable under applicable law, such
provisions will be excluded from this Note and the balance of the Note will be interpreted as if such provisions were so excluded and this Note will be enforceable in accordance with its terms. 

7.11 Acknowledgment. For the avoidance of doubt, it is acknowledged that the Holder will be entitled to the benefit of
all adjustments in the number of shares of the Company s capital stock as a result of any splits, recapitalizations, combinations or other similar transactions affecting the Company’s capital stock underlying the Conversion Shares that occur
prior to the conversion of this Note. 
 7.12 Further Assurances. From time to time, the parties will execute and
deliver such additional documents and will provide such additional information as may reasonably be required to carry out the terms of this Note and any agreements executed in connection herewith. 

7.13 Limitation on Interest. In no event will any interest charged, collected or reserved under this Note exceed the
maximum rate then permitted by applicable law, and if any payment made by the Company under this Note exceeds such maximum rate, then such excess sum will be credited by the Holder as a payment of principal. 

  
 6 

 7.14 Officers and Directors not Liable. In no event will any officer
or director of the Company be liable for any amounts due and payable pursuant to this Note. 
 7.15 Waiver of Jury
Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS NOTE, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER REPRESENTS AND
WARRANTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 

7.16 Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief. The remedies provided in this Note
shall be cumulative and in addition to all other remedies available under this Note, at law or in equity (including, without limitation, a decree of specific performance and/or other injunctive relief), no remedy contained herein shall be deemed a
waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit a Holder’s right to pursue actual damages for any failure by Borrower to comply with the terms of this Note. Amounts set forth or provided for
herein with respect to payments and the like (and the computation thereof) shall be the amounts to be received by Holder and shall not, except as expressly provided herein, be subject to any other obligation of Borrower (or the performance thereof).
Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable and material harm to Holder and that the remedy at law for any such breach may be inadequate. Therefore, Borrower agrees that, in the event of any such
breach or threatened breach, Holder shall be entitled, in addition to all other available rights and remedies, at law or in equity, to seek and obtain such equitable relief, including but not limited to an injunction restraining any such breach or
threatened breach, without the necessity of showing economic loss and without any bond or other security being required. 
 IN WITNESS
WHEREOF, Borrower has executed and delivered this Note as of the date first written above. 
  

			
	HEART TEST LABORATORIES, INC.
		
	By:	 	  

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]